Genetic polymorphism in pathogenesis of irritable bowel syndrome.
Irritable bowel syndrome (IBS) is a complex symptom-based disorder without established biomarkers or putative pathophysiology. IBS is a common functional gastrointestinal disorder which is defined as recurrent abdominal pain or discomfort that has at least two of the following symptoms for 3 d per month in the past 3 mo according to ROME III: relief by defecation, onset associated with a change in stool frequency or onset with change in appearance or form of stool. Recent discoveries revealed genetic polymorphisms in specific cytokines and neuropeptides may possibly influence the frequencies and severity of symptoms, as well as the therapeutic responses in treating IBS patients. This review gives new insights on how genetic determinations influence in clinical manifestations, treatment responses and potential biomarkers of IBS.
['Cheung|Cynthia K Y|CK|', 'Wu|Justin C Y|JC|']
D016207:Cytokines D003672:Defecation D005819:Genetic Markers D020022:Genetic Predisposition to Disease D006801:Humans D043183:Irritable Bowel Syndrome D009479:Neuropeptides D010641:Phenotype D011110:Polymorphism, Genetic D011379:Prognosis D012307:Risk Factors
Genetic polymorphism Irritable bowel syndrome Cytokines Endocannabinoids Psychiatric distress Serotonin